Ambrx Granted Orphan Drug Designation for ARX788 for the Treatment of Gastric Cancer
Ambrx was granted orphan drug designation by the FDA for its drug ARX788, which is in clinical trials to treat HER2-positive gastric... Read More
Zolbetuximab Plus EOX vs EOX Alone for First-Line Treatment of Advanced CLDN18.2-Positive Gastric and Gastro-Oesophageal Adenocarcinoma
In a phase 2 trial in advanced gastric cancer with high expression of CLDN18.2, adding Ganymed Pharmaceuticals’experimental drug zolbetuximab to chemotherapy improved... Read More
Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma
Adding Herceptin to chemotherapy improved outcomes for patients with HER2-positive advanced gastric cancer in a clinical trial.
Tumor Response and Symptom Palliation from RAINBOW, a Phase III Trial of Ramucirumab Plus Paclitaxel in Previously Treated Advanced Gastric Cancer
The targeted drug Cyramza combined with chemotherapy produced a disease-control rate of 81% in a trial of previously treated gastric cancer patients.
Adjuvant chemotherapy is superior to chemoradiation after D2 surgery for gastric cancer
Chemotherapy after surgery for gastric cancer was superior to chemoradiation in a recent trial.
Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100
The PD-L1 inhibitor Bavencio, when given as maintenance therapy to gastric cancer patients in a trial, was not superior to chemotherapy, but... Read More
Five Prime Announces Bemarituzumab Plus Chemotherapy Demonstrates Significant Progression-Free and Overall Survival Benefit Compared to Placebo Plus Chemotherapy in Front-Line Advanced Gastric and Gastroesophageal Junction Cancer
Five Prime Therapeutics’ FGFR2b-targeted drug combined with chemotherapy improved survival in a phase 2 trial.
Gritstone Oncology Advances into Phase 2 Expansion Cohorts for its Personalized Neoantigen Immunotherapy GRANITE and its Off-the-Shelf Neoantigen Immunotherapy SLATE
Gritstone Oncology has expanded a phase 2 clinical trial of its personalized cell therapy to include patients with gastric cancer.
Oncologie Announces New Data and Analyses from Clinical Programs and Name Change to OncXerna Therapeutics
In a trial combining Keytruda with Oncologie’s investigational drug that targets phosphatidylserine, the response rate was 43% among patients with a low... Read More
Frontline Nivolumab/Chemo Combo Improves Survival in Gastric/GEJ Cancer and Esophageal Adenocarcinoma
Bristol Myers Squibb’s Opdivo improved survival in previously untreated gastric cancer patients in a trial presented at ESMO20.